Goldman Sachs Initiates Hemab Buy
Goldman Sachs initiates coverage of Hemab Therapeutics with a buy rating due to its potential in treating rare diseases. This could positively impact the stock.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.